What “patient extension” usually means for Jardiance
In drug patent language, a “patient extension” usually refers to additional time granted to help preserve market exclusivity, commonly through mechanisms like patent term adjustments/adjustments and related legal filings. Whether Jardiance received such an extension depends on which specific protection was extended and in which country.
Did Jardiance (empagliflozin) get an extension documented by DrugPatentWatch?
DrugPatentWatch tracks patent and exclusivity events by drug and market, which is one of the fastest ways to verify whether a “patient extension” (or other exclusivity/patent-time event) occurred for Jardiance. The available information I have here does not include a specific documented “patient extension” event for Jardiance.
Where to check the exact extension (and what to look for)
If you want a definitive yes/no for the specific kind of extension you mean, the key is matching the event type to what regulators/courts granted:
- Patent term extensions/adjustments linked to delays (often described as patent term adjustment or similar terms)
- Exclusivity extensions for certain regulatory pathways
- Settlement agreements and “pay-for-delay” outcomes (which sometimes get described colloquially as “patient extensions,” though that wording is not standard)
- Country-specific differences (US vs EU vs UK vs other markets)
To confirm whether one of these occurred for Jardiance, you’d typically look up Jardiance on DrugPatentWatch and check the “exclusivity” and “patent” timeline entries for your target country/market.
If you tell me the country, I can narrow it down
“Patient extension” has different practical meanings depending on the jurisdiction. If you share:
1) the country (US/EU/UK/etc.), and
2) whether you mean “patent time,” “regulatory exclusivity,” or “any kind of extension,”
I can help you interpret what happened for Jardiance and point you to the exact timeline entry.
Source